Puretech Health files patent for Grna for modifying CD7 gene in genetically engineered cells

Summary

The article discusses Puretech Health's patent filing for a novel guide RNA (gRNA) designed to genetically modify cells, specifically targeting the CD7 gene in the context of hematopoietic malignancies. It highlights the use of CRISPR/Cas nucleases for introducing the gRNA into cells, describing potential applications in gene therapy. Key biotechnological tags include Biotechnology, Molecular biology, Molecular genetics, Immune system, T cells, Guide RNA, CAR T cell, Gene therapy, Stem cell, and Genetic engineering. The article's source is the United States Patent and Trademark Office (USPTO), credited to Puretech Health Plc.